悦耳易
Lv54
1540 积分
2023-12-22 加入
-
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial
2小时前
已完结
-
Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis
2天前
已完结
-
2025CSCO胃癌诊疗指南
10天前
已关闭
-
中国肝细胞癌合并门静脉癌栓诊疗指南(2021年版)
11天前
已完结
-
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes
1个月前
已完结
-
Digital Biomarkers for Neurodegenerative Disease
1个月前
已完结
-
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
2个月前
已完结
-
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
2个月前
已完结
-
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2个月前
已完结
-
A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer's disease
2个月前
已完结